With the deep globalization of the pharmaceutical industry, can the top position of the United States remain evergreen?

To describe the current world drug R & D pattern with a paragraph is very vivid: the United States is the leader; Japan and the European Union run side by side; Japan's leading innovation is the follow-up; most Chinese enterprises are running or lagging behind Of course, the world's pharmaceutical research and development pattern in Europe and the United States is currently the largest in medical research, and the largest in drug research and development is still the United States In 2000, US companies developed 29 of the 75 best-selling drugs in the world According to pharmexec's ranking in the top 50 of global prescription drug sales data (see the table below), it reflects the current global pharmaceutical research and development pattern In the top 50, the number of us enterprises is the highest, with a total of 16, accounting for 32%, and if calculated by amount, it accounts for 45% In 2018, the world's top 50 pharmaceutical companies in prescription drug sales, Japan's modern medicine originated in the west, and the research and development of European and American medicine occupy a congenital advantage After World War II, the situation changed The Japanese government increased its investment in science and technology in the pharmaceutical industry In 2007, the "five year strategic plan for innovative drugs and medical devices" was launched to expand the market share of innovative drugs and medical devices in Japan (see the table below for the investment of various departments of the Japanese government in innovative drugs and medical device research) according to the top 50 prescription drug sales of global pharmaceutical enterprises in 2018, Japanese enterprises accounted for 10 seats, accounting for 20% of the total, and became a pharmaceutical power in line with European and American powers According to the Pharmaceutical Association Guide of Japan Pharmaceutical Industry Association, Japan's R & D capacity of new drugs ranks the third in the world, second only to the United States and Europe On the one hand, Japan's new drug research and development benefits from solid basic research From the fact that Japan has won 18 Nobel prizes in 18 years, it can be seen that Japan's basic research is at the top level in the world On the other hand, many Japanese enterprises have successfully transformed from generic pharmaceutical enterprises to innovative ones, such as Sino foreign pharmaceutical, Takeda pharmaceutical, Astaire, the first three Communist Party, Ono pharmaceutical, etc It is worth noting that Japan's new drugs are not all independently developed, and many new effective ingredients depend on the introduction from abroad, which is also worth learning from China in the development India's pharmaceutical industry has continued to grow strongly for half a century, ranking third in the world in terms of the number of pharmaceutical products produced, and it is a big country of generic drugs Apart from the patent system set up by India in the 1970s in favor of local enterprises in spite of the international patent protection law, India has good chemical expertise and technical talents in the process of globalization of the pharmaceutical industry With its language advantages, its quality system certification ability of file application is strong More importantly, India actively meets the market challenges of the standard system in developed countries By means of measures such as the maturity of the pharmaceutical industry and cost competitive drugs, India has made up for the backward infrastructure and other problems In addition to generic drugs, India has a strong supply of raw (auxiliary) materials From the figure below, we can see the number of American DMF held by Chinese, Indian, American and European pharmaceutical companies From the perspective of DMF declaration, China's number has been growing year by year since 2000, especially after 2010, with a large growth rate, but the number of DMF holdings is still poor compared with India's Distance Although the number of DMF held by Chinese, Indian, American and European pharmaceutical companies in the United States over the years has improved, and human beings have a deeper understanding of the micro biological system, the drug discovery process is still a relatively "long, expensive, complex and inefficient" process With huge investment and very low discovery rate, it is difficult for R & D innovative drugs to obtain high returns in a single national market A good innovative drug must be targeted at the global market, and even R & D and production are carried out through global cooperation With the deepening of opening-up, China's Drug Administration officially joined the International Conference for the coordination of human drug registration technology (ICH), which means that domestic drug research and development is gradually integrated with Europe and the United States, opening a good start towards internationalization; in China, the reform of drug review and approval is vigorously promoted, and pharmaceutical enterprises are facing a reshuffle, which may be difficult for small and medium-sized enterprises, but for large enterprises Innovation oriented enterprises, on the other hand, are "relying on their strength to send me to Qingyun" According to the current development trend of China's drug research and development, in the near future, China's pharmaceutical enterprises will definitely occupy a place in the global drug research and development field With the deep globalization of the pharmaceutical industry, can the top position of the United States be evergreen? What do you think? To get more data information, please refer to "China Pharmaceutical R & D 40 years big data", more surprises waiting for you! Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.